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Abstract 30	  
The aim of this study was to explore the potential of fused-deposition 3-dimensional 31	  
printing (FDM 3DP) to produce modified-release drug loaded tablets. Two isomers 32	  
used in the treatment of inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-33	  
ASA, mesalazine) and 4-aminosalicylic acid (4-ASA), were selected as model drugs. 34	  
Commercially-produced polyvinyl alcohol (PVA) filaments were loaded with the drugs 35	  
in an ethanolic drug solution. A final drug-loading of 0.06% w/w and 0.25% w/w was 36	  
achieved for the 5-ASA and 4-ASA strands, respectively. 10.5 mm diameter tablets of 37	  
both PVA/4-ASA and PVA/5-ASA were subsequently printed using an FDM 3D 38	  
printer, and varying the weight and densities of the printed tablets was achieved by 39	  
selecting the infill percentage in the printer software. The tablets were mechanically 40	  
strong, and the FDM 3D printing was shown to be an effective process for the 41	  
manufacture of the drug, 5-ASA. Significant thermal degradation of the active 4-ASA 42	  
(50%) occurred during printing, however, indicating that the method may not be 43	  
appropriate for drugs when printing at high temperatures exceeding those of the 44	  
degradation point. The results of the dissolution tests conducted in modified Hank’s 45	  
buffer showed that release profiles for both drugs were dependent on both the drug 46	  
itself and on the infill percentage of the tablet. Our work here demonstrates the 47	  
potential role of FDM 3DP as an efficient and low-cost alternative method of 48	  
manufacturing individually-tailored oral drug dosage, and also for production of 49	  
modified-release formulations.  50	  
 51	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Introduction 57	  
Personalized, or individualized, medicinal products offer a number of advantages to 58	  
patients worldwide. Not only do they reduce the incidence of adverse effects by 59	  
tailored avoidance of over- or under-dosing individual patients as well as potentially 60	  
increasing the ease of delivery, but also in improving adherence to therapy by 61	  
providing a greater focus on one-to-one clinical management. Underpinned by recent 62	  
technological advancements, there is a growing emphasis on realizing the value of 63	  
developing such dosage forms by the pharmaceutical industry. Indeed, such value is 64	  
not merely limited to tailoring individual doses per se, but in expanding the field to 65	  
involve use of novel manufacturing techniques producing limited numbers of dosage 66	  
forms either at the point of dispensing, or even at the point of use by the patient. To 67	  
this end, one example of a novel manufacturing technique is that of 3-dimensional 68	  
printing (3DP), which has so far demonstrated use in applications printing solid oral 69	  
dosage forms suitable for human consumption, and is widely regarded as 70	  
revolutionary in the field of pharmaceutical technology [1-3]. 3DP could be seen as a 71	  
natural evolution from the related and currently-investigated methods of ink-jet 72	  
printing, though whose potential as a manufacturing method is more limited to the 73	  
printing of drug solutions onto flat substrates [4, 5], such as oral wafers [6], or the 74	  
obtaining of aqueous droplets [7, 8].  75	  
By contrast, 3DP allows for the fabrication of a three-dimensional solid object of 76	  
virtually any shape from a digital model by building up repetitively layer-by-layer, the 77	  
intended object to create the final solid form. In the context of manufacturing 78	  
pharmaceutical dosage forms, different type of systems have so far been used in the 79	  
manufacture of zero-order release tablets [9], implants [10-14], bilayer tablets [15] or 80	  
fast-dissolving devices comprising powder contained in a polymeric shell [16, 17].  81	  
A more recent development in 3DP technology that is both cost-effective and allows 82	  
for the fabrication of hollow objects and pharmaceutical-grade polymers is that which 83	  
involves the application of fused-deposition modelling (FDM), whereby a polymer is 84	  
heated and extruded through a small tip of between 50-100 µm, and thereafter 85	  
solidifies on a build plate. This allows for more precise control of droplet size, drug 86	  
release and reproducibility, and therefore potentially for the personalization of drug 87	  
therapy. However, this concept has yet to be formally evaluated as a means of 88	  
manufacturing drug-loaded unit dosage forms. 89	  
The application of the FDM technology to simplify the manufacturing process and 90	  
improve on the inherent properties and delivery of dosage forms may show clinically 91	  
relevant significance for specific diseases, whereas some issues as the influence of 92	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the printing temperature and the selection of the polymers on the stability of the 93	  
drugs to be printed must be firstly evaluated. 94	  
For the purpose of this study we have selected two aminosalicylates as model drugs. 95	  
Aminosalicylates are first-line therapies of the many drugs used in the treatment of 96	  
inflammatory bowel disease (IBD). 5-aminosalicylic acid (5-ASA) - the most 97	  
commonly used- is considered to be the most efficacious of the aminosalicylates, and 98	  
is consequently widely prescribed. A second aminosalicylate drug – 4-aminosalicylic 99	  
acid (4-ASA) which is more commonly employed as an anti-tuberculosis agent rather 100	  
than one included in treatment strategies for IBD – was also investigated. The 101	  
chemical structure of 4-ASA is only distinguished from 5-ASA by the position of its 102	  
NH2 group (Figure 1), though this small variation is sufficient to affect all of the 103	  
biological activity of the isomers, their melting points, and their respective solubilities, 104	  
though their molecular weights are otherwise identical (153.13g/mol).  105	  
 106	  
The specific aims of this work were to evaluate the feasibility of printing tablets 107	  
loaded with the drugs 4-ASA and 5-ASA using an FDM 3DP, and to explore whether 108	  
varying the print settings allows for control over the dissolution kinetics of the final 109	  
tablet, thereby offering a new method of manufacturing controlled-release dosage 110	  
forms. The drug stability during the 3D printing process and the drug release 111	  
performance in the biorrelevant media modified Hank’s buffer (bicarbonate buffer) 112	  
were also evaluated.  113	  
 114	  
Materials and Methods 115	  
Materials  116	  
Filament: 117	  
Polyvinyl alcohol (PVA, a water-soluble synthetic polymer represented by the formula 118	  
(C2H4O)n) was purchased as an extruded filament (1.75mm diameter, print 119	  
temperature 190-220°C, batch No: 2013-10-18, Makerbot Inc., USA). 120	  
 121	  
Drugs: 122	  
5-aminosalicylic acid (5-ASA) was obtained from PharmaZell GmbH, Raubling, 123	  
Germany, water-solubility 840 mg/mL [18] and 4-aminosalicylic acid (4-ASA) was 124	  
purchased from VWR International Ltd., Poole, UK, water solubility 1690 mg/L [19]  125	  
 126	  
	   5	  
Absolute ethanol of analytical grade and salts for preparing buffer dissolution media 127	  
were acquired from VWR International Ltd., Poole, UK. 128	  
 129	  
Methods 130	  
Preparation of PVA filament loaded with drug: 15g of the commercially available 131	  
filament of PVA (~5 m) were immersed in a 100mL beaker containing 50 mL of 132	  
ethanol where 500mg of the drug (5-ASA or 4-ASA) were dispersed. The saturated 133	  
ethanolic dispersions of the drug with the filaments were covered with parafilm to 134	  
avoid the evaporation of the ethanol and kept under magnetic stirring for 24h. The 135	  
drug-loaded filaments were then place on a tray, dried in an oven at 60°C to constant 136	  
weight (approximately for 1.5h) and finally stored in a vacuum desiccator. The drug-137	  
loading of the filaments was determined by HPLC analysis (below). 138	  
 139	  
 140	  
Printing of 5-ASA and 4-ASA tablets: Tablets were fabricated with the previously 141	  
drug-loaded filaments using a commercial fused-deposition modelling 3D printer, 142	  
MakerBot Replicator 2 Desktop 3D printer (MakerBot Inc, USA). The templates used 143	  
to print the tablets were designed with MakerWare Software (v. 2.2.2). The selected 144	  
size for the tablet was X=10.54mm, Y=10.45mm and Z=3.79mm, as the size of an 145	  
average table. The printer settings that were found to produce the best tablets for 146	  
both drugs were: standard resolution with the raft option activated and an extrusion 147	  
temperature of 210 °C, speed while extruding (90mm/s), speed while traveling 148	  
(150mm/s), number of shells (2) and layer height (0.20mm). The infill percentage was 149	  
varied (10%, 50% or 90%) in order to produce tablets of different characteristics 150	  
(Table 1 and Figure 2). 151	  
 152	  
Thermal characterization of the model drugs, filament and the drug-loaded filaments: 153	  
 154	  
Differential scanning calorimetry (DSC) 155	  
Measurements were performed on Q2000 DSC (TA instruments, Waters, LLC, USA) 156	  
with heating rate of 10°C/min. Calibration for cell constant and enthalpy was 157	  
performed with indium (Tm = 156.6°C, ∆Hf =28.71 J/g) according to the manufacturer 158	  
instructions. Nitrogen was used as a purge gas with a flow rate of 50ml/min for all the 159	  
experiments. Data were collected with TA Advantage software for Q series (version 160	  
2.8.394), and analysed using TA Instruments Universal analysis 2000. All melting 161	  
temperatures were reported as extrapolated onset unless otherwise stated. TA 162	  
aluminum pans and lids (Tzero) were used with an average sample size of 8-10mg.  163	  
	   6	  
 164	  
Thermogravimetrical analysis (TGA) 165	  
Samples were heated at 10°C/min in open aluminium pans using TA Instruments 166	  
Discovery TGA (TA instruments, Waters, LLC, USA). Nitrogen was used as a purge 167	  
gas with a flow rate of 25 ml/min. Data collection and analysis were performed using 168	  
TA Instruments Trios software and % mass loss and/or onset temperature were 169	  
calculated. 170	  
 171	  
Characterization of the tablets: 172	  
 173	  
Determination of tablet morphology 174	  
Dimensions of the tablets (diameter and thickness) were measured using a digital 175	  
calliper. Pictures of the tablets were taken with a Nikon CoolpixS6150 with the macro 176	  
option of the menu. 177	  
 178	  
Determination of tablet hardness 179	  
The hardness (Crushing strength) of ten tablets of each type was measured using a 180	  
traditional Tablet Hardness Tester TBH 200 (Erweka GmbH, Heusenstamm, 181	  
Germany), whereby an increasing force is applied perpendicular to the tablet axis to 182	  
opposite sides of a tablet until the tablet fractures. The units of force employed to 183	  
quantify breaking force were Newtons.  184	  
 185	  
Determination of tablet friability 186	  
Approximately 6.5 g of tablets were weighed and placed into the drum of a Friability 187	  
Tester Erweka	   type	  TAR	  10	   (Erweka	  GmbH,	  Heusenstamm,	  Germany).	  The	  drum	  was	  188	   then	  rotated	  at	  25	  rpm	  for	  4	  min	  and	  the	  sample	  re-­‐weighed.	  The	  friability	  of	  the	  sample	  189	   is	  given	  in	  terms	  of	  weight	  loss,	  expressed	  as	  a	  percentage	  of	  the	  original	  sample	  weight.	  	  190	  
 191	  
Determination of drug loading  192	  
A tablet or a section of drug-loaded strand before printing (approx. 0.3g) were placed 193	  
in a 1L volumetric flask containing deionized (DI) water under magnetic stirring until 194	  
complete dissolution. Samples for analysis were then filtered through 0.45 µm filters 195	  
(Millipore Ltd, Ireland) and concentration of drug was determined by HPLC (n=2).  196	  
Concentrations of 4-ASA in the samples were measured by HPLC-UV (Hewlett 197	  
Packard 1050 Series HPLC system, Agilent Technologies, UK). The validated high 198	  
performance liquid chromatographic assay entailed pumping a mobile phase, 199	  
consisting of acetonitrile (24%), water (76%) and orthophosphoric acid (900 µL/L), 200	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through a Discovery HSF5 column (4.6 x 150 mm) maintained at 40 °C. The mobile 201	  
phase was pumped at a flow rate of 1 mL/min and the eluent was screened at a 202	  
wavelength of 303 nm. Samples for analysis were injected (20 µL) onto a reverse 203	  
phase (5 µm particle size) column (Supelco, Pennsylvania, USA).  204	  
Concentrations of 5-ASA were determined by injecting 20 µL sample onto a HPLC-205	  
UV (Hewlett Packard 1050 Series HPLC system, Agilent Technologies, UK). The 206	  
validated high performance liquid chromatographic assay entailed pumping a mobile 207	  
phase, consisting of methanol (5%), water (95%) and trifluoroacetic acid (500 µL/L), 208	  
through a reverse phase column: 5 µm particle size, 4.6 x 150 mm, Discovery HSF5 209	  
(Supelco, Pennsylvania, USA). The mobile phase was pumped at 40 °C at a flow 210	  
rate of 1 mL/min and the eluent was screened at a wavelength of 228 nm. 211	  
 212	  
Dissolution testing 213	  
Drug release profiles from the 3DP tablets were obtained using a USP-II apparatus 214	  
(Model PTWS, Pharmatest, Germany). In each assay, the tablets were placed at the 215	  
bottom of the vessel and were stirred (50 rpm) in dissolution medium (900 mL) at 216	  
37°C. Tests were conducted in triplicate under sink conditions. During the dissolution 217	  
test, samples of 4-ASA were automatically removed and filtered through 0.1mm 218	  
filters and drug concentration was determined using an in-line UV spectrophotometer 219	  
(Cecil 2020, Cecil Instruments Ltd., Cambridge, UK) operated at 302 nm. Data were 220	  
processed using Icalis software (Icalis Data Systems Ltd, Berkshire, UK). In the case 221	  
of 5-ASA, drug concentration was determined using the HPLC method described 222	  
previously due to the low absorbance of the drug and interference with the polymer. 223	  
 224	  
Tablets were tested in a modified bicarbonate buffer (pH 6.8) controlled by an Auto 225	  
pH SystemTM [20]. Bicarbonate buffer was chosen because of its better resemblance 226	  
to the physiological characteristics of gastrointestinal fluid (pH, ionic composition and 227	  
buffer capacity) [21]. The medium, adapted from Hank’s buffer, is primarily a 228	  
bicarbonate buffer, in which bicarbonate (HCO3-) and carbonic acid (H2CO3) co-exist 229	  
in equilibrium, along with dissolved CO2.  Adjusting the concentration of carbonic acid 230	  
(H2CO3) and bicarbonate (HCO3-) allows control of the buffer pH. Purging the solution 231	  
with carbon dioxide, which promotes the formation of carbonic acid, decreases the 232	  
pH. Similarly, purging with an inert gas (such as Helium) which removes dissolved 233	  
CO2 from the solution reduces the carbonic acid to bicarbonate ratio, increases the 234	  
pH. The purging of gases is regulated by an Auto pH SystemTM, automatically 235	  
triggered by a pH feedback from the solution. Controlling the pH of the medium to pH 236	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6.8 simulates the pH conditions of the small intestine. Additionally, other components 237	  
are added to simulate the ionic strength and composition of gastrointestinal fluid 238	  
(136.9 mM NaCl, 5.37 mM KCl, 0.812 mM MgSO4.7H2O, 1.26 mM CaCl2, 0.337 mM 239	  
Na2HPO4.2H2O, 0.441 mM KH2PO4, 4.17 mM NaHCO3, CO2 quantity sufficient to 240	  
maintain the pH at 6.8). 241	  
 242	  
Results and discussion 243	  
 244	  
The manufacture of solid dosage forms incorporating 4-ASA or 5-ASA by FDM 3DP 245	  
fabrication was performed by use of a commercially-extruded PVA polymer.  246	  
 The PVA filaments are the only water-soluble commercially-available filaments used 247	  
in 3D printing to date. They are generally used to print sections of plastic devices that 248	  
can be lately removed by placing the object in water. Here the PVA filaments used 249	  
were loaded from an ethanolic rather than aqueous solution, the latter of which was 250	  
shown to result in undesirable and rapid dissolution of the PVA filament during trial 251	  
attempts. The drug (4-ASA or 5-ASA) loaded into the pre-extruded PVA polymer 252	  
followed a method identical to the loading of hydrogels: In this way, the polymer 253	  
filament was placed in the drug solution before being removed and dried. Based on 254	  
the assumption that no chemical interaction occurs between the drug and polymer, 255	  
the drug passively diffuses into the polymer matrix and is trapped following the drying 256	  
phase. This ensures that the diameter of the polymer filament remains constant, and 257	  
is therefore easily extruded by the printer. The method is also cheap, versatile and 258	  
requires little development other than selection of a suitable solvent. 259	  
Final drug-loading in the strands were relatively low, however, at 0.24% w/w for 4-260	  
ASA and four-fold lower at 0.06 w/w for 5-ASA.The more reduced drug-loading for 5- 261	  
ASA is likely due to the near-insolubility in ethanol as compared to the ethanol-262	  
soluble 4-ASA [22]. This fact reveals the importance of the selection of the solvent of 263	  
the drug solution and could open paths to optimize drug loading into the strands.  264	  
 265	  
Analysis of the 4-ASA content of 3D printed tablets showed a reduction in drug 266	  
content to 0.12% w/w, indicating that around half the drug was thermally degraded as 267	  
it passed through the heated extruder of the printer (210 ºC). This is likely due to the 268	  
fact that 4-ASA melts and decomposes at temperatures between 130-145ºC as 269	  
shown by TGA and DSC data obtained for 4-ASA (Fig. 3). 270	  
 271	  
Indeed, selection of this drug enabled us to determine that there is a significant drug 272	  
degradation when printing at temperatures higher than that of the decomposition 273	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temperature of the drug, even though the residence time in the print head might be 274	  
small (on the order of seconds). By comparison, printed tablets of the more thermally 275	  
stable 5-ASA did not show any reduction in drug content during the printing process, 276	  
attributable to the fact that the printing temperature (210 ºC) is lower than that of the 277	  
degradation point of 5-ASA. Analysis of TGA and DSC (Fig. 3) confirm that 5-ASA is 278	  
stable up to 230°C as 1.5% weight loss is shown and it starts to melt/degrade around 279	  
278-279°C.  280	  
In this case, we have probed that the use of FDM 3D printer is suitable for fabricating 281	  
tablets of those drugs with melting points distinct (higher and lower) from the 282	  
temperature required for the 3D printing process. The results, however, suggest that 283	  
the method may not be appropriate for fabrication of solid dosage forms with drugs 284	  
when printing at temperatures higher than that of the degradation temperature of the 285	  
drug. 286	  
The thermal analysis of the PVA indicates that the filament melts around 180°C (Fig. 287	  
4) and the weight loss of around 4%w/w shown in the TGA curve before its melting 288	  
point is most likely because of water evaporation. A separate experiment in the TGA 289	  
where PVA was held isothermally at 100°C resulted in a weight loss of about 4% 290	  
water. The degradation of PVA appears to occur just after melting starts and up to 291	  
260°C only ~3.5% is degraded. The DSC thermograms of drug-loaded filaments 292	  
indicate both drugs interacting with PVA upon heating as reflected by the change in 293	  
shape of the melting endotherm of PVA. As 5-ASA has a higher melting point than 294	  
that of filament, it is most likely to dissolve in the molten PVA. 4-ASA has a much 295	  
lower melting point and possibly its degradation while the PVA is melting is affecting 296	  
the latter’s melting process.  297	  
Some technological approaches could enable overcoming the inconveniences of 298	  
printing at temperatures higher than the degradation temperature of the drug, for 299	  
instances in the future the use of other polymer filaments with melting temperatures 300	  
below the melting point of the drug.  301	  
 302	  
The tablet template per se was imported into the Makerware software prior to printing 303	  
as a stereolithography (.stl) file, which only encodes the surface data of the object to 304	  
be printed and requires the thickness of the surface to be defined in order to print the 305	  
desired object(s). The effect of varying the infill percentage on the physical 306	  
characteristics of the tablets (size and weight) and on the drug release were also 307	  
investigated to determine the impact on these parameters, and hence to allow for 308	  
manufacture optimization. The infill percentage which controls both the density and 309	  
mechanical strength of the object can be set during the printing process or adjusted 310	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in order to modulate physical properties of the resulting object; if no infill is printed, 311	  
the resulting object will be hollow. Through such modulation, and by varying these 312	  
parameters, the dissolution profile of the tablets printed can also be altered: Herein, 313	  
tablets were printed with three different infill percentages (10, 50 and 90%). It can be 314	  
seen from Table 1 and the photographs in Figure 2 that the tablet weights expectedly 315	  
increased with an increasing infill percentage. The size of the tablets remains almost 316	  
constant (the tablet thickness increases slightly while increasing the infill), with 317	  
resulting tablets demonstrating high reproducibility in physical dimensions, along with 318	  
high mechanical strength resistant to damage on handling.  319	  
The characteristics of these 3D tablets make that some parameters usually 320	  
measured in tablets manufactured with tableting machines reveals unnecessary. For 321	  
example the friability of all the formulations was 0%, showing that the 3D tablets are 322	  
more than suitable for technological process as coating, handling or packaging.  323	  
The hardness data show values between 330 and 390N for the tablets of 10 % infill 324	  
and close to 485 N for those with higher % infill. The obtained values of harness of 325	  
the tablets do not actually represent crushing strength, since the tablet does not 326	  
break. The values obtained from the 10% infill tablets correspond with the value of 327	  
deformation of the tablet; for tablets with higher % infill, the values represent approx. 328	  
the maximum value measured by the tablet hardness tester. 329	  
 330	  
Dissolution testing of both 4–ASA and 5-ASA printed tablets was subsequently 331	  
conducted in Hank’s bicarbonate buffer (pH 6.8), given that bicarbonate buffers are 332	  
considered to be more closely representative of human small intestinal fluid than 333	  
phosphate or other compendial buffer systems [23, 24]. Patterns of drug release 334	  
were shown to differ according to the drug formulated and the infill percentage 335	  
(Figure 5): For 5-ASA, the dissolution profiles were identical during the first hour of 336	  
testing, with 50% drug release and the total drug release reached in less than 4 337	  
hours for all formulations. However, faster drug release was observed from those 338	  
formulations tested featuring a lower infill percentage.  339	  
The dissolution profiles of 4-ASA tablets by contrast were more dependent on the 340	  
infill percentage of the tablets. Here, 10% infill tablets showed complete release after 341	  
4 hours dissolution, but both the 50 and 90% infill tablets showed burst release 342	  
followed by slow release, indicating that a greater infill percentage was responsible 343	  
for slowing the rate of drug release. The dissolutions data thus confirm that it is 344	  
indeed possible to modulate the dissolution profile of 3DP tablets by careful selection 345	  
of the printing parameters, given that a faster drug release can be obtained lowering 346	  
the infill percentage. Gupta et al [25] showed that the swelling ratio of PVA hydrogels 347	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was dependent on polymer concentration, with higher concentrations resulting in 348	  
reduced swelling ratios. As such, it is this effect which may be controlling the release 349	  
profiles of both 4-ASA and 5-ASA from the printed tablets. A reduction of the size of 350	  
the formulations during the dissolutions tests is observed, suggesting that erosion 351	  
processes may be involved in the mechanisms responsible for drug release from this 352	  
3D printed formulations, though on the other hand our results here show also the 353	  
significance of the model drug’s role on the drug release profile. 354	  
 355	  
Conclusion 356	  
Here, we have formulated and produced tablets containing the drugs 4-ASA and 5-357	  
ASA via a 3D printing method with varying infill percentages, demonstrating the 358	  
feasibility of using FDM 3DP to fabricate drug-loaded tablets.  359	  
The FDM 3D printing can be considered as an effective process for the production of 360	  
tablets incorporating drugs such 5-ASA. On the other hand, the substantial 361	  
degradation of the drug 4-ASA (50%) during the 3D printing process suggests that 362	  
the method may not be appropriate, however, for the manufacture of drugs when 363	  
printing at temperatures higher than that of the drug degradation temperature. The 364	  
high extrusion temperature (210 ºC) needed to print with PVA strands is a potential 365	  
drawback, whereas the use of other polymer filaments may enable to print at 366	  
temperatures below the decomposition temperature of the drug to avoid the 367	  
degradation.  368	  
Moreover, we have also demonstrated considerable differences of dissolution profiles 369	  
in the biorrelevant media modified Hank’s buffer (bicarbonate buffer) for the two 370	  
isomers (4-ASA and 5-ASA) manufactured by this approach, highlighting the 371	  
importance of drug selection on the release profile. Furthermore, we have shown that 372	  
the release profiles obtained can be also modified by selection of the printing 373	  
parameters. The infill percentage modulates the dissolution profile and a faster drug 374	  
release can be obtained lowering the infill percentage of the tablets.  375	  
This initial study, indeed, demonstrates the feasibility of fabricating personalized 376	  
medicines and modified-release dosage forms by FDM 3DP, despite of the low doses 377	  
of both 4-ASA and 5-ASA.Further developments and refinements in the field will 378	  
enable this promising approach to become a bona fide method of producing 379	  
personalized medicines.  380	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Figure Caption 457	  
 458	  
Figure 1. Chemical structure of 5-ASA (left) and 4-ASA (right) 459	  
 460	  
Figure 2: Images of the 3DP fabricated tablets as a function of infill percentage 461	  
 462	  
Figure 3. TGA and DSC plots for A) 4-ASA and B) 5-ASA.  463	   	  464	  
Figure 4. TGA and DSC plots for A) PVA filament B) 4-ASA-loaded filament and C) 465	  
5-ASA-loaded filament.	  466	   	  467	  
Figure 5: Dissolution profiles of 3DP tablets with varying infill percentages in modified 468	  
Hank’s buffer (pH 6.8) 469	  
 470	  
